Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center

Kanwal P.S. Raghav, MD, MBBS, of MD Anderson Cancer Center

Dr Raghav on a Phase 2 Study of ABBV-400 Plus Fluorouracil, Folinic Acid, and Bevacizumab in Pretreated Metastatic CRC

ByKanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center

January 26th 2025

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC.

Exciting Treatment Opportunities in mCRC

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

May 28th 2021

Closing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.

Decisions for Sequencing Therapy for HER2-Expressing mCRC

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

May 28th 2021

Considerations regarding best sequencing strategies with novel therapies to treat HER2-mutated metastatic colorectal cancer.

Novel Therapies for HER2-Expressing mCRC

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

May 28th 2021

Implications for treating patients with HER2-expressing metastatic colorectal cancer with novel agents such as trastuzumab deruxtecan and tucatinib.

Novel Combinations Being Investigated for mCRC Treatment

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

May 21st 2021

Current trials exploring novel combinations that show potential in making microsatellite stable tumors hot and amenable to response to immunotherapy in metastatic colon cancer.

Dual I-O Therapy for mCRC

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

May 21st 2021

Drs Cathy Eng and Joleen M. Hubbard discuss the rationale for studying dual immunotherapy approaches for metastatic colorectal cancer treatment.

Best Practices Surrounding IO Treatment for mCRC

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

May 14th 2021

Kanwal Raghav, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses when it is most appropriate to initiate immunotherapy for metastatic colorectal cancer, highlighting the roles of tumor mutation burden and microsatellite instability as biomarkers for treatment.

Frontline I-O Treatment for mCRC

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

May 14th 2021

Cathy Eng, MD, FACP, FASCO, describes data revealed by the KEYNOTE-177 trial and discusses best practices for using immunotherapy as first-line treatment of metastatic colorectal cancer.

Biomarker Testing and Precision Medicine in mCRC

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

May 7th 2021

A panel of gastrointestinal oncologists discuss current options for molecular testing based on the understanding that predictive biomarkers play a role in the management of metastatic colon cancer.

Fruquintinib for Refractory mCRC

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

May 7th 2021

Expectations regarding the use of fruquintinib, an oral VEGF tyrosine kinase inhibitor, as third-line therapy for metastatic colorectal cancer.

Best Strategies for Sequencing Regorafenib in mCRC

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 30th 2021

Considerations for how to sequence therapy with regorafenib for relapsed or refractory metastatic colorectal cancer based on the REVERCE II study.

TAS-102 for Refractory mCRC

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 30th 2021

Variables that impact patient selection for TAS-102 treatment as later-line therapy for metastatic colorectal cancer and considerations for using TAS-102 in combination with bevacizumab.

Regorafenib as Later-Line Treatment for mCRC

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 23rd 2021

The rationale for treating metastatic colon cancer with regorafenib in a later-line setting and the importance of applying the dose-escalation strategy demonstrated by the ReDOS trial into clinical practice.

BRAF-Mutated mCRC: Treating With the BEACON Regimen

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 23rd 2021

Gastrointestinal oncologists consider when it is most appropriate to initiate the BEACON trial regimen of encorafenib-binimetinib-cetuximab as treatment for BRAF-mutated metastatic colorectal cancer.

Treatments for BRAF-Mutated mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 16th 2021

Considerations for treating BRAF-mutated metastatic colorectal cancer with the combination of a BRAF inhibitor plus anti-EGFR agent based on recently presented data.

Second-Line Treatment of mCRC: Rechallenging Therapy

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, The University of Texas MD Anderson Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 16th 2021

The role of molecular assays, including liquid biopsies, in providing information on resistance mechanisms in metastatic colorectal cancer and the impact of testing results on decisions for rechallenging with a previous therapy.

Preferences for Second-Line Therapy for mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 9th 2021

Drs Cathy Eng and Joleen M. Hubbard explain how patients with metastatic colon cancer typically respond to initial treatment and describe the factors that impact second-line treatment decisions.

Maintenance Therapy for Metastatic CRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 9th 2021

Recommendations regarding the selection, initiation, and length of maintenance therapy to help manage cases of metastatic colon cancer.

Applying Aggressive Therapy to Treat mCRC Up Front

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 2nd 2021

The rationale for treating select patients with metastatic colorectal cancer with intensive therapy in the first-line setting vs waiting until disease progression.

Colorectal Cancer in a Younger Population

ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 2nd 2021

Cathy Eng, MD, FACP, FASCO, of Vanderbilt-Ingram Cancer Center reacts to the increasing rate of colorectal cancer among the younger population and highlights topics that apply specifically to counseling younger patients.

Optimizing mCRC Treatment: Decision-Making With Patients

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

March 25th 2021

An overview of topics that oncologists should counsel patients on when working with them to select therapy to treat metastatic colon cancer.

Initial Strategies for Assessing and Treating mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

March 25th 2021

Experts in gastrointestinal oncology highlight their approaches to assessing patients with newly diagnosed metastatic colorectal cancer and explain the variables that factor into first-line treatment decisions.